Search

Your search keyword '"Negoro, Shunichi"' showing total 292 results
Start Over Author "Negoro, Shunichi"
292 results on '"Negoro, Shunichi"'

1. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations

Author

Uchibori, Ken, Satouchi, Miyako, Sueoka-Aragane, Naoko, Urata, Yoshiko, Sato, Akemi, Imamura, Fumio, Inoue, Takako, Tachihara, Motoko, Kobayashi, Kazuyuki, Katakami, Nobuyuki, Kokan, Chiyuki, Hirashima, Tomonori, Iwanaga, Kentaro, Mori, Masahide, Aoe, Keisuke, Morita, Satoshi, and Negoro, Shunichi

Published
2018
Full Text
View/download PDF

4. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)

Author

Nishino, Kazumi, Imamura, Fumio, Kumagai, Toru, Katakami, Nobuyuki, Hata, Akito, Okuda, Chiyuki, Urata, Yoshiko, Hattori, Yosihihiro, Tachihara, Motoko, Yokota, Souichirou, Nishimura, Takashi, Kaneda, Toshihiko, Satouchi, Miyako, Morita, Satoshi, and Negoro, Shunichi

Published
2015
Full Text
View/download PDF

6. Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003)

Author

Hata, Akito, Katakami, Nobuyuki, Hattori, Yoshihiro, Tanaka, Kosuke, Fujita, Shiro, Kotani, Yoshikazu, Nishimura, Takashi, Imamura, Fumio, Yokota, Soichiro, Satouchi, Miyako, Monden, Kazuya, Otsuka, Kojiro, Nishiyama, Akihiro, Tsubouchi, Kazuya, Kaneda, Toshihiko, Yoshioka, Hiroshige, Morita, Satoshi, and Negoro, Shunichi

Published
2017
Full Text
View/download PDF

8. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study

Author

Kubota, Kaoru, Hida, Toyoaki, Ishikura, Satoshi, Mizusawa, Junki, Nishio, Makoto, Kawahara, Masaaki, Yokoyama, Akira, Imamura, Fumio, Takeda, Koji, Negoro, Shunichi, Harada, Masao, Okamoto, Hiroaki, Yamamoto, Nobuyuki, Shinkai, Tetsu, Sakai, Hiroshi, Matsui, Kaoru, Nakagawa, Kazuhiko, Shibata, Taro, Saijo, Nagahiro, and Tamura, Tomohide

Published
2014
Full Text
View/download PDF

13. A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

Author

Hata, Akito, Katakami, Nobuyuki, Fujita, Shiro, Nanjo, Shigeki, Takeshita, Jumpei, Tanaka, Kosuke, Kaneda, Toshihiko, Nishiyama, Akihiro, Nishimura, Takashi, Nakagawa, Atsushi, Otsuka, Kojiro, Morita, Satoshi, Urata, Yoshiko, and Negoro, Shunichi

Published
2015
Full Text
View/download PDF

14. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer

Author

Niho, Seiji, Kunitoh, Hideo, Nokihara, Hiroshi, Horai, Takeshi, Ichinose, Yukito, Hida, Toyoaki, Yamamoto, Nobuyuki, Kawahara, Masaaki, Shinkai, Tetsu, Nakagawa, Kazuhiko, Matsui, Kaoru, Negoro, Shunichi, Yokoyama, Akira, Kudoh, Shinzoh, Kiura, Katsuyuki, Mori, Kiyoshi, Okamoto, Hiroaki, Sakai, Hiroshi, Takeda, Koji, Yokota, Soichiro, Saijo, Nagahiro, and Fukuoka, Masahiro

Published
2012
Full Text
View/download PDF

22. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Author

Mitsudomi, Tetsuya, Morita, Satoshi, Yatabe, Yasushi, Negoro, Shunichi, Okamoto, Isamu, Tsurutani, Junji, Seto, Takashi, Satouchi, Miyako, Tada, Hirohito, Hirashima, Tomonori, Asami, Kazuhiro, Katakami, Nobuyuki, Takada, Minoru, Yoshioka, Hiroshige, Shibata, Kazuhiko, Kudoh, Shinzoh, Shimizu, Eiji, Saito, Hiroshi, Toyooka, Shinichi, Nakagawa, Kazuhiko, and Fukuoka, Masahiro

Published
2010
Full Text
View/download PDF

31. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non–small cell lung cancer

Author

Urata, Yoshiko, Okamoto, Isamu, Takeda, Masayuki, Hattori, Yoshihiro, Okuno, Keiko, Shimada, Temiko, Kurata, Takayasu, Kaneda, Hiroyasu, Miyazaki, Masaki, Terashima, Masaaki, Tanaka, Kaoru, Morita, Satoshi, Nakagawa, Kazuhiko, Negoro, Shunichi, and Satouchi, Miyako

Published
2013
Full Text
View/download PDF

35. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

Author

Noda, Kazumasa, Nishiwaki, Yutaka, Kawahara, Masaaki, Negoro, Shunichi, Sugiura, Takahiko, Yokoyama, Akira, Fukuoka, Masahiro, Mori, Kiyoshi, Watanabe, Koshiro, Tamura, Tomohide, Yamamoto, Seiichiro, and Saijo, Nagahiro

Subjects
Lung cancer, Small cell, Etoposide -- Evaluation, Cisplatin -- Evaluation
Abstract

The chemotherapy drugs irinotecan and cisplatin appear to be more effective than etoposide and cisplatin for treating small-cell lung cancer, according to a study of 154 patients. After two years, 19% of the patients who received irinotecan and cisplatin were still alive, compared to 5% of the patients who received etoposide and cisplatin.

Published
2002

41. Phase I and pharmacologic study of oral (E)-2 -deoxy-2 -(fluoromethylene) cytidine: on a daily x 5-day schedule

Author

Masuda, Noriyuki, Negoro, Shunichi, Takeda, Kouji, Takifuji, Nobuhide, Hirashima, Tomonori, Yana, Takashi, Kurata, Noriaki, Kuwabara, Takashi, Kobayashi, Satoshi, Kudoh, Shinzoh, Matsui, Kaoru, Takada, Minoru, and Fukuoka, Masahiro

Subjects
Fluorometholone -- Research, Pyrimidine nucleotides -- Dosage and administration, Pyrimidine nucleotides -- Research, Cancer -- Drug therapy, Pharmaceuticals and cosmetics industries
Abstract

Byline: Noriyuki Masuda (1), Shunichi Negoro (2), Kouji Takeda (2), Nobuhide Takifuji (2), Tomonori Hirashima (2), Takashi Yana (1), Noriaki Kurata (3), Takashi Kuwabara (3), Satoshi Kobayashi (3), Shinzoh Kudoh (1), Kaoru Matsui (1), Minoru Takada (1), Masahiro Fukuoka (4) Keywords: phase I trial; ribonucleoside diphosphate reductase inhibitor; deoxytidine analog; FMdC Abstract: (E)-2 -deoxy-2 -(fluoromethylene)cytidine (FMdC), one of the most potent inhibitors of ribonucleoside diphosphate reductase, was selected for clinical development because of its novel mechanisms of action, and strong antitumor activity against experimental tumor models. This study was designed to determine the toxicities, maximum-tolerated dose (MTD), and pharmacokinetic profile of FMdC. FMdC was given orally for 5 consecutive days every 3 or 4 weeks in patients with advanced solid tumors. The starting dose was 8 mg/m2/day. Pharmacokinetic studies were carried out on days 1 through 5 of the first cycle. Ten patients with non-small cell lung cancer received 15 courses of FMdC at doses which were de-escalated from 8 mg/m2/day to 2 mg/m2/day because of unexpected severe toxicities at the starting dose level. Neutropenia was the dose-limiting toxicity. Thrombocytopenia and anemia were mild. Flu-like symptoms and fever were the common non-hematologic toxicities. The MTD was 4 mg/m2/day, since four of six patients developed grade 3--4 neutropenia. At the 4 mg/m2/day dose level, the mean terminal half-life, maximum plasma concentration (Cmax), plasma clearance, and mean residence time on day 1 were 3.20 h, 15.8 ng/ml, 2.91 l/h/kg, and 4.03 h, respectively. The recommended dose for phase II studies with this schedule is also 4 mg/m2/day for 5 days. Further investigations are necessary to establish optimal dosing schedules and routes for the administration of FMdC. Author Affiliation: (1) Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Habikino, Osaka, Japan (2) Department of Respiratory Disease, Osaka City General Hospital, Miyakojima, Osaka, Japan (3) Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan (4) Department of Internal Medicine, Kinki, University School of Medicine, Osaka, Japan Article History: Registration Date: 29/09/2004

Published
1998

42. Phase II Study of Etoposide and Cisplatin With Concurrent Twice-Daily Thoracic Radiotherapy Followed by Irinotecan and Cisplatin in Patients With Limited-Disease Small-Cell Lung Cancer: West Japan Thoracic Oncology Group 9902

Author

Saito, Hiroshi, Takada, Yoshiki, Ichinose, Yukito, Eguchi, Kenji, Kudoh, Shinzoh, Matsui, Kaoru, Nakagawa, Kazuhiko, Takada, Minoru, Negoro, Shunichi, Tamura, Kenji, Ando, Masahiko, Tada, Takuhito, and Fukuoka, Masahiro

Published
2006
Full Text
View/download PDF

43. Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

Author

Kudoh, Shinzoh, Takeda, Koji, Nakagawa, Kazuhiko, Takada, Minoru, Katakami, Nobuyuki, Matsui, Kaoru, Shinkai, Tetsu, Sawa, Toshiyuki, Goto, Isao, Semba, Hiroshi, Seto, Takashi, Ando, Masahiko, Satoh, Taroh, Yoshimura, Naruo, Negoro, Shunichi, and Fukuoka, Masahiro

Published
2006
Full Text
View/download PDF

45. Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101).

Author

Yamaguchi, Masafumi, Tada, Hirohito, Mitsudomi, Tetsuya, Seto, Takashi, Yokoi, Kohei, Katakami, Nobuyuki, Nakagawa, Kazuhiko, Oda, Makoto, Ohta, Mitsunori, Sawa, Toshiyuki, Yamashita, Motohiro, Iked, Norihiko, Saka, Hideo, Higashiyama, Masahiko, Nomori, Hiroaki, Semba, Hiroshi, Negoro, Shunichi, Chiba, Yasutaka, Shimokawa, Mototsugu, and Fukuoka, Masahiro

Subjects
NON-small-cell lung carcinoma, TUMOR classification, GEMCITABINE, OVERALL survival
Abstract

Background: Adjuvant oral uracil-tegafur (UFT) has led to significantly longer postoperative survival among patients with non-small-cell lung cancer (NSCLC). Gemcitabine (GEM) monotherapy is also reportedly effective for NSCLC and has minor adverse events (AEs). This study compared the efficacy of GEM- versus UFT-based adjuvant regimens in patients with completely resected pathological stage (p-stage) IB–IIIA NSCLC. Patients and methods: Patients with completely resected p-stage IB–IIIA NSCLC were randomly assigned to GEM or UFT. The primary endpoint was overall survival (OS); secondary endpoints were disease-free survival (DFS), and AEs. Results: We assigned 305 patients to the GEM group and 303 to the UFT group. Baseline factors were balanced between the arms. Of the 608 patients, 293 (48.1%) had p-stage IB disease, 195 (32.0%) had p-stage II disease and 121 (19.9%) had p-stage IIIA disease. AEs were generally mild in both groups, and only one death occurred, in the GEM group. After a median follow-up of 6.8 years, the two groups did not significantly differ in survival: 5 year OS rates were GEM: 70.0%, UFT: 68.8% (hazard ratio 0.948; 95% confidence interval 0.73–1.23; P = 0.69). Conclusion: Although GEM-based adjuvant therapy for patients with completely resected stage IB–IIIA NSCLC was associated with acceptable toxicity, it did not provide longer OS than did UFT. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study

Author

Sueoka-Aragane, Naoko, Katakami, Nobuyuki, Satouchi, Miyako, Yokota, Soichiro, Aoe, Keisuke, Iwanaga, Kentaro, Otsuka, Kojiro, Morita, Satoshi, Kimura, Shinya, Negoro, Shunichi, and Hanshin-Saga Collaborative Cancer Study Group

Subjects
molecular targeted therapy, DNA, lung neoplasms, mutation, erbB-1, respiratory tract diseases
Abstract

Use of plasma DNA to detect mutations has spread widely as a form of liquid biopsy. EGFR T790M has been observed in half of lung cancer patients who have acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI). Effectiveness of monitoring T790M via plasma DNA during treatment with EGFR-TKI has not been established as an alternative to re-biopsy. This was a prospective multicenter observational study involving non-small cell lung cancer patients carrying EGFR L858R or exon 19 deletions, treated with EGFR-TKI. The primary objective was to determine whether T790M could be detected using plasma DNA in patients with progressive disease (PD). T790M was examined using the mutation-biased PCR and quenching probe (MBP-QP) method, a sensitive, fully-automated system developed in our laboratory. Eighty-nine non-small cell lung cancer patients were enrolled from seven hospitals in Japan. Sequential examinations revealed T790M in plasma DNA among 40% of patients who developed PD. Activating mutations, such as L858R and exon 19 deletions, were detected in 40% of patients using plasma DNA, and either T790M or activating mutations were observed in 62%. Dividing into four periods (before PD, at PD, at discontinuation of EGFR-TKI and subsequently), T790M was detected in 10, 19, 24 and 27% of patients, respectively. Smokers, males, patients having exon 19 deletions and patients who developed new lesions evidenced significantly frequent presence of T790M in plasma DNA. Monitoring T790M with plasma DNA using MBP-QP reflects the clinical course of lung cancer patients treated with EGFR-TKI. Detection of T790M with plasma DNA was correlated with EGFR mutation type, exon 19 deletions and tumor progression. Re-biopsy could be performed only in 14% of PD cases, suggesting difficulty in obtaining re-biopsy specimens in practice. Monitoring T790M with plasma DNA reflects the clinical course, and is potentially useful in designing strategies for subsequent treatment.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results